Discover Great Companies Discover Great Clients
Popularity  2.5万   |   Followers  14   |   Likes  9   |   Feedback  7 Claim this company

A high-tech enterprise specializing in new drug research and developme

No.685 Nanjing Popularity Ranking No.69 Qixia District Jiangsu No.2 Fa Jiao Gong Yi No.3 Hua He Products Design Compositing No.6 Zhong Liu Yao Products No.9 Kang Zhong Liu Yao No.10 Chemicals Engineering No.12 Yi Yao Jing Ji No.14 Pharmaceutical APIs No.15 APIs No.16 Yi Yao Xin Yao No.18 Xin Yao R&D No.22 Innovative Drugs No.29 Sheng Wu Ke Ji / Biotechnology Engineering 高新技术企业 省级高新技术企业 科技型中小企业 市科技型中小企业 省科技型中小企业 市级创新型中小企业
More

Company Overview

  • Nature: Private Enterprise Size: 50-99 employees Founded: 20年
  • Industry: Pharmaceuticals/Bioengineering 、 Raw Materials and Processing
  • Full name: Nanjing Cavendish Biotechnology Engineering Co., Ltd.。

Development Stage

  • Ranking: Ranked #685 in Nanjing by popularity Ranked #2 in Nanjing Fa Jiao Gong Yi Company by popularity Ranked #3 in Nanjing Hua He Products Design Compositing Company by popularity Ranked #6 in Nanjing Zhong Liu Yao Products Company by popularity Ranked #9 in Nanjing Kang Zhong Liu Yao Company by popularity
  • Honors: 高新技术企业 省级高新技术企业 According to algorithm
  • Salary: 53.5% of positions earn 6-10K, In 2026 vs last yeargrew by 24%.。Master's salary: ¥28.0K.
  • R&D: "Medical & Health/Beauty & Healthcare" demand: 34.5%, "Biology/Pharmaceutical/Chemical/Environmental Protection": 34.5%, "Other (R&D and Technical)": 10.3%。
  • Recruiting: In 2026 vs 2025decreased by 22%. Demand for highly educated talent: Master's: 4.
  • Requirement: Education: 大专 leads with 43.1%. Experience: 不限 leads with 36.2%.
  • Region: Distributed across 2 regions, 南京: 48.3%, 泰州: 46.6%, 武汉: 5.2%.

About the Company

[Summary] A high-tech enterprise specializing in new drug research and developme

Nanjing Cavendish Biotechnology Engineering Co., Ltd. is a high-tech enterprise specializing in new drug research and development. The company was established in November 2006 with a registered capital of RMB 80 million. The company is committed to the research and development of innovative new drug technologies, MAH production, and academic promotion services for developed drugs. Key development areas include anti-tumor drugs (hematological diseases), diabetes drugs, cardiovascular drugs, and anti-infective drugs. All new drugs initiated for research and development are breakthrough therapeutic products in their original treatment fields, striving to add new treatment options to fill gaps in domestic disease treatment areas.
Main business:
The company is primarily engaged in the research and development of innovative new drug technologies. Its main business includes new drug technology transfer, patented technology licensing, holding new drug production approvals (MAH) for contracted manufacturing and sales, academic promotion services for developed drugs, and also accepting collaborative development and contracted development of new drug projects from external parties.
Research and Innovation
In 2010, the company invested in the construction of the F5 R&D office building in Jiangsu Life Science and Technology Innovation Park, Xianlin University Town, Nanjing, equipped with comprehensive and advanced R&D equipment and facilities, with total R&D equipment assets exceeding RMB 50 million. The company has excellent and experienced technical talent support in the field of new drug research, possessing an experienced team for scientific research and industrial implementation. It currently has a research team of nearly 100 professionals in medicinal chemistry, pharmaceutics, pharmaceutical analysis, chemical engineering technology, biological fermentation, and other professional fields. Investment in new drug R&D has increased year by year, exceeding RMB 100 million in 2018.
R&D Achievements:
From 2009 to 2016, the company initiated more than 50 research projects. Around these projects, 42 Chinese invention patent applications were filed, with 22 patents authorized; 8 international invention patent applications were submitted through the PCT route, designated to enter Europe, the United States, Japan, South Korea, Australia, and other countries respectively, with 25 patents authorized.
Representative successfully developed products:
Lenalidomide used for the treatment of multiple myeloma and myelodysplastic syndromes. Our lenalidomide project has currently been approved for marketing. Multiple patented inventions of this project have obtained patent authorization protection in China as well as in the United States and Europe. Listed in China as the first generic drug under patent challenge, our developed lenalidomide has a legitimate basic foundation for patent intellectual property rights, advancing the market launch time of this product in China by nearly 7 years.
In 2023, the company obtained the drug registration approval for "Eplerenone Tablets" among the earlier batches nationwide. This drug is an excellent variety marketed in China, filling the gap in domestic second-generation MRA drugs. The successful development and marketing of blockbuster products marks the company's development entering a new stage, laying a solid foundation with core competitiveness for embracing the era of innovation-driven development in the pharmaceutical industry.
Honors Received:
The company has been recognized as a "High-tech Enterprise," "Jiangsu Province Specialized, Refined, Distinctive and Innovative SME," "Jiangsu Province Technology-based SME," "Nanjing Engineering Technology Center," "Jiangsu Province Patent Implementation Plan Promotion Unit," "Nanjing Qixia District Intellectual Property Advanced Unit," and "Nanjing Qixia District Science and Technology Innovation Advanced Collective."

The company currently offers the following job positions. Outstanding talents who meet the requirements and are interested in joining our team are welcome to contact our Human Resources Department. We welcome your calls! Looking forward to your joining!

Expand
Information is aggregated from the web and may not be exact. For reference only.
Information incorrect? Claim this company to edit

Cavendish Biotech How Fast Is Hiring Growing? (14 open positions)

Manage
?
Growth Rate
2026 vs 2025
  • 2025: Down 23%
  • 2024: Up 53%
  • 2023: Up 89%
  • 2022: Down 7%
Cavendish Biotech Year-by-Year Hiring:
* Hiring was generally low during 2020-2022 due to the pandemic
Cavendish Biotech Campus Recruitment & Advanced Degree Talent Demand
Master's 4
Note: How fast is hiring at Nanjing Cavendish Biotechnology Engineering Co., Ltd. growing? Cavendish Biotech2026: 47 openings (down 22%), 2025: 60 openings (down 23%), 2024: 78 openings (up 53%), 2023: 51 openings (up 89%), 2022: 27 openings (down 7%), 2021: 29 openings. A rising curve may indicate expansion; a falling curve may indicate slower growth or good retention. Based on publicly available data, for reference only.

Cavendish Biotech Master's Degree Job Demand Analysis

(More)
?
Growth Rate
2026 vs 2025
  • 2025: Down 56%
  • 2024: Up 13%
Cavendish Biotech Master's Hiring by Year:
* Hiring was generally low during 2020-2022 due to the pandemic
How fast is master's hiring at Nanjing Cavendish Biotechnology Engineering Co., Ltd. growing? Cavendish BiotechMaster's recruitment over the years: 2025: 4 openings (down 56%), 2024: 9 openings (up 13%), 2023: 8 openings.

Cavendish Biotech Doctoral Degree Job Demand Analysis

(More)
N/A
Growth Rate
Cavendish Biotech Doctoral Hiring by Year: 2024 — same as 2023
* Hiring was generally low during 2020-2022 due to the pandemic
How fast is doctoral hiring at Nanjing Cavendish Biotechnology Engineering Co., Ltd. growing? Cavendish BiotechDoctorate recruitment over the years: 2024: 3 openings (up 13%), 2023: 3 openings.

Cavendish Biotech R&D Strength (Technical Talent Demand)

(More)
How is the demand for technical talent at Nanjing Cavendish Biotechnology Engineering Co., Ltd.? Based on an analysis of Cavendish Biotech's job postings over the past year, "Medical & Health/Beauty & Healthcare" demand: 34.5%, "Biology/Pharmaceutical/Chemical/Environmental Protection": 34.5%, "Other (R&D and Technical)": 10.3%, "Mechanical/Instrumentation": 10.3%, "Scientific Research": 8.6%, "Computer/Network/Technology": 3.4%. For reference only.

Cavendish Biotech — What Are the Salaries Like? (58 records)

Manage
Cavendish Biotech Salary Overview
salary range: 2K - 50K, 53.5% of roles pay ¥6-10K
Note: salary statistics are based on 58 salary records from the past year and depend on the job sample. For reference only.
How is the salary at Nanjing Cavendish Biotechnology Engineering Co., Ltd.?Cavendish Biotech53.5% of positions earn 6-10K, Undergraduate salary: ¥。Nanjing salary ranking top 40,工厂生产类 average salary ¥14.2K。 Note: Based on analysis of job postings, does not represent current on-the-job positions; system stability may affect objectivity. For reference only.Data inaccurate? Let us know

Salaries for hot jobs of Cavendish Biotech

(More)
Are salaries high at Nanjing Cavendish Biotechnology Engineering Co., Ltd.? We provide: Team Leader, QA, 临床, Analyst, Researcher, 医学专员, Medical Manager, On-site Representative, ehs, QC, 制剂研究, Operator, 环保, Pharmaceutical Formulation Scientist, Drug Synthesis Specialist, Equipment Operator, Project Supervisor, Project Lead, Warehouse Staff, 保洁. Click to view detailed salary analysis by job.

Cavendish Biotech honors, qualifications & industry associations

Job Category

  • 工厂生产类
    60.3% of total 60.3%
  • 医疗卫生/美容保健类
    34.5% of total 34.5%
  • 生物/制药/化工/环保类
    34.5% of total 34.5%
  • 质量管理类
    22.4% of total 22.4%

Education

  • 大专
    43.1% of total 43.1%
  • 硕士
    27.6% of total 27.6%
  • 本科
    20.7% of total 20.7%
  • 高中
    6.9% of total 6.9%

Experience

  • 不限
    36.2% of total 36.2%
  • 5-10年
    27.6% of total 27.6%
  • 1-3年
    20.7% of total 20.7%
  • 3-5年
    15.5% of total 15.5%
View Detailed Analysis

What does Nanjing Cavendish Biotechnology Engineering Co., Ltd. require? Who is Cavendish Biotech hiring? Cavendish Biotech recruitment: 工厂生产类占比最多占60.3%,其次是医疗卫生/美容保健类占34.5%. What education can get in at Cavendish Biotech? 大专占比最多占43.1%,其次是硕士占27.6%. High education required at Cavendish Biotech? 硕士占27.6%. Work experience required at Cavendish Biotech? 不限占比最多占36.2%,其次是5-10年占27.6%. Where are the job locations at Cavendish Biotech? 南京占比最多占48.3%,其次是泰州占46.6%. Based on job postings from the past year, for reference only.

Business Registration

Provided by

Operating Status: 开业
Registered Capital: 8,000万(元)
Legal Representative: 许永翔
Date Established:
Credit Code: 913201137937221689
Registered Address: 南京市栖霞区仙林街道仙林大学城纬地路9号

Partners & Suppliers

与双鹭药业合作开发来那度胺的合成工艺,双鹭取得该品种国内首仿。 Source
合作客户 药物研发服务
南京卡文迪许与南京大学合作研发 Source
供应商 高校/研究院合作
南京卡文迪许与南京医科大学合作研发 Source
供应商 高校/研究院合作
南京卡文迪许与中国药科大学合作研发 Source
供应商 高校/研究院合作
南京卡文迪许向安捷伦采购分析仪器 Source
供应商 实验仪器

People who follow Cavendish Biotech also follow

Cavendish Biotech Competitors (Similar Companies)

农药中间体 化肥/农药 氨基酸 医药中间体
制药/药业 药物研发 仿制药 创新药
“国家大型农药生产企业”
制药/药业 医药 单抗药物 临床前研究
医药 药物研发 医药服务 新药研发
制药/药业 医药
“致力于开发、生产和销售符合国际规范和质量标准的治疗性抗体药物”
医药 药物研发 生物医药 原料药
“Leading enterprise in the field of central nervous system drugs in Chi”
“Products for the diagnosis and treatment of allergic diseases”
“Adhering to the corporate culture of science and excellence, committed”
“For many consecutive years, it has maintained a leading position in do”
医药 生物医药 原料药 化学原料药
制药/药业 医药 生物化学 化学制药
“A renowned enterprise in China's liver disease and anti-tumor fields”

Discover Great Companies, Discover Great Clients

南京公司名录 南京“Qixia District”公司名录 南京“生物科技/生物工程”公司名录 南京“抗肿瘤药”公司名录 南京“肿瘤药物”公司名录 南京“制药/药业”公司名录 南京“新药研发”公司名录 附近的公司

Report

*Reason:

Radical political or ideological topics
Advertising or spam
Pornographic or vulgar content
Obscene language or personal attacks
Other

Congratulations, submitted successfully!

Your edit is under review. You will be notified by email within 1 business day.

Submission failed.

Followed successfully. We'll notify you of any company updates.

Help others learn about this company, add my impression of this company»

Log in with the following accounts to save your follows

Followed successfully, we'll notify you of any company updates